Forest Must Resolve Breakpoint Issues On Road To Ceftaroline Approval
Executive Summary
Negotiation of breakpoints appears to be the final hurdle as Forest Laboratories seeks approval for ceftaroline fosamil to treat serious skin infections and community-acquired bacterial pneumonia.
You may also be interested in...
FDA Raises Breakpoints In Final Labeling For Forest's Ceftaroline
FDA demonstrated a willingness to be flexible about antibiotic breakpoints in its Oct. 29 approval of Forest Laboratories' ceftaroline fosamil.
FDA Raises Breakpoints In Final Labeling For Forest's Ceftaroline
FDA demonstrated a willingness to be flexible about antibiotic breakpoints in its Oct. 29 approval of Forest Laboratories' ceftaroline fosamil.
FDA's New Skin Infection Endpoint Needs Refinement, Advisory Panel Says
The new endpoint proposed in FDA’s recent acute bacterial skin and skin structure infections guidance – cessation of lesion spread – needs further refinement to be a reliable assessment of antibiotic efficacy, according to members of the agency’s Anti-Infective Drugs Advisory Committee.